PharmaceuticalMetabolicThyromimeticThyroid metabolite

Tiratricol (TRIAC)

Also known as TRIAC · Triacana · Tiratricol

Written by enwyReviewed 5 Aug 20261 sources0 comments

Tiratricol (3,3',5-triiodothyroacetic acid, TRIAC) is a naturally occurring metabolite of T3 with high affinity for thyroid receptor beta. Clinically used in thyroid hormone resistance and MCT8 deficiency, it is used in bodybuilding as a fat-loss agent claimed to spare the heart relative to T3.

01 Overview

TRIAC is the acetic-acid analogue of triiodothyronine and acts as a thyromimetic with a short half-life and preferential activity at TR-beta receptors, which mediate lipid and metabolic effects more than cardiac ones. It has genuine clinical roles in resistance to thyroid hormone and in Allan-Herndon-Dudley syndrome.

In the cutting context it is dosed for its thermogenic and lipolytic action. Its rapid clearance means users split doses through the day. Despite claims of cardiac sparing, supraphysiologic dosing still suppresses TSH and can cause thyrotoxic symptoms.

02 Mechanism

Binds thyroid hormone receptors with a preference for TR-beta, driving transcription of metabolic and lipid genes and suppressing TSH; the beta preference gives a lower cardiac-to-metabolic effect ratio than T3.

03 Dosing

Tier	Dose	Route	Notes
Cutting	1000–3000 mcg/day	Oral	Split into 2-3 doses due to short half-life
Resistance to thyroid hormone	1400–2800 mcg/day	Oral	Clinical dosing under specialist care

04 Effects

Effect	Magnitude	Evidence
Fat loss / increased metabolic rateThermogenic action mobilises fat during a deficit.	Raised BMR	Observational
Cholesterol reductionTR-beta activation upregulates hepatic LDL clearance.	Lower LDL	Clinical
Relatively lower cardiac stimulationTR-beta preference reduces tachycardia versus equipotent T3, though not eliminated.		Preclinical

05 Side effects

Effect	Severity	Frequency	Evidence
TSH suppressionStrongly suppresses pituitary TSH even at modest doses.	Moderate	Universal	Clinical
Thyrotoxic symptomsPalpitations, sweating, tremor and heat intolerance at high doses.	Moderate	Dose-dependent	Clinical
Muscle lossCatabolism of lean tissue in an energy deficit.	Moderate	Common	Observational

06 Legal status

Marketed as Triacana (Rx)

as of Jan 2026

United States

Not FDA-approved; sold as supplement in some markets

FDA has warned against tiratricol-containing supplements · as of Jan 2026

07 References

TRIAC (tiratricol) in resistance to thyroid hormoneEuropean Journal of Endocrinology

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.